Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial
Kleefstra N, Houweling ST, Bilo HJ
Published in Diabetes Care
Methodology
Randomized, double-blind, placebo-controlled trial of chromium picolinate 500 or 1000 microg/day for 6 months in insulin-treated obese patients with type 2 diabetes.
Key Findings
No significant differences in HbA1c, insulin requirements, lipids or body weight between chromium and placebo groups.
Conclusions
Chromium picolinate had no effect on glycemic control in this Western obese, insulin-treated type 2 diabetes population.
Limitations
Single population with adequate chromium status, moderate sample size, 6-month duration.
Supplements Studied
Chromium picolinate had no effect on HbA1c, insulin requirements, lipids or body weight in insulin-treated type 2 diabetes.
Outcomes Measured
Chromium had no effect on insulin requirements or glycemic control.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.